FIGURE

Fig. 5

ID
ZDB-FIG-160429-17
Publication
Lipscomb et al., 2016 - Dasatinib as a treatment for Duchenne muscular dystrophy
Other Figures
All Figure Page
Back to All Figure Page
Fig. 5

The effect of dasatinib treatment on levels of phosphorylated and non-phosphorylated β-dystroglycan in sapje zebrafish larvae. Lysates were made from sapje–/– embryos treated from 24 hpf until 96 hpf with dasatinib or DMSO-only. (A) Western blots probed with antibodies for p-β-DG and α-tubulin. (B) The density of the blot probed for p-β-DG was quantified relative to α-tubulin levels in each sample, and normalized to the average control signal. There is a significant decrease in the level of phosphorylated β-dystroglycan in larvae treated with dasatinib, compared with controls. (C) Western blots probed with antibodies for β-DG and α-tubulin. Numbers in (A and C) represent relative position of molecular weight markers in kDa. (D) The density of the blot probed against β-DG was quantified relative to α-tubulin levels in each sample, and normalized to the average control signal. There was a significant difference in the levels of β-DG in larvae between different treatment groups. Graphs show mean + SEM of at least six samples for each treatment, from three independent experiments. One-way ANOVA was carried out followed by Dunnett′s multiple comparison test (ns, non-significant; ***P < 0.001).

Expression Data
Gene:
Antibodies:
Fish:
Condition:
Anatomical Term:
Stage: Day 4

Expression Detail
Antibody Labeling
Phenotype Data
Fish:
Condition:
Observed In:
Stage: Day 4

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Hum. Mol. Genet.